ストックスクリーナーアプリを入手
20.24
1.79%
-0.45
前日終値:
$20.69
開ける：
$20.61
24時間の取引高:
135.98K
Relative Volume:
0.06
時価総額：
$15.26B
収益：
$956.00K
当期純損益:
$-196.68M
株価収益率:
-84.33
EPS:
-0.24
ネットキャッシュフロー:
$-113.02M
1週間 パフォーマンス:
+2.47%
1か月 パフォーマンス:
+12.20%
6か月 パフォーマンス:
-10.25%
1年 パフォーマンス:
+519.51%
1日の値動き範囲:
$20.01
$20.63
1週間の範囲:
$19.13
$20.82
52週間の値動き範囲:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
SMMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
20.25 | 15.26B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.18 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
656.77 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
289.38 | 37.63B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
609.12 | 37.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
255.13 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | Goldman | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics - Benzinga
Summit CEO Bob Duggan Sued Over 'Outlandish' Self-Dealing Loan - Bloomberg Tax
Is Summit Therapeutics a Millionaire Maker? - Nasdaq
Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Overweight Recommendation - Nasdaq
Summit rises as Cantor becomes latest to launch with a bullish view - MSN
Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - Nasdaq
Summit Therapeutics grants stock options to new employees By Investing.com - Investing.com Canada
Summit Therapeutics grants stock options to new employees - Investing.com India
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:20 pm EDT - Marketscreener.com
Summit Therapeutics Awards 147,500 Shares in Strategic Employee Stock Options - StockTitan
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Summit stock rises after Cantor's bullish view (SMMT:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Initiates Summit Therapeutics at Overweight -March 21, 2025 at 07:27 am EDT - Marketscreener.com
This Unstoppable Biotech Stock Just Became an Even Better Buy - The Globe and Mail
Summit Therapeutics Names Robert LaCaze as Chief Commercial Officer -March 18, 2025 at 03:30 am EDT - Marketscreener.com
Summit Therapeutics : Completion of $50 million Fundraising and Directorate Change - Marketscreener.com
Billion-Dollar Oncology Expert Robert LaCaze to Drive Summit Therapeutics Cancer Drug Launch - StockTitan
Evercore ISI Group Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Outperform Recommendation - Nasdaq
Summit gains as Evercore highlights potential to rival Merck’s Keytruda - MSN
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:SMMT - Benzinga
(SMMT) On The My Stocks Page - Stock Traders Daily
Summit Therapeutics issues stock options to new employees By Investing.com - Investing.com Australia
Summit Therapeutics issues stock options to new employees - Investing.com India
Summit Therapeutics Stock Climbs 4%, Share Price Hits $19.96 - TradingPedia
Why Summit Therapeutics Stock Was Winning This Week - MSN
SMMT Gains on Bullish Analyst Coverage - GuruFocus.com
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Evercore ISI - Defense World
Is Summit Therapeutics Inc. (SMMT) the Best Multibagger Stock to Buy in 2025? - Insider Monkey
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year - Nasdaq
Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target -March 12, 2025 at 12:08 pm EDT - Marketscreener.com
Summit Therapeutics Shares Surge on Promising Trial Results - TipRanks
Evercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform Recommendation - Nasdaq
Summit Therapeutics initiated with an Outperform at Evercore ISI - TipRanks
12 Best Multibagger Stocks to Buy in 2025 - Insider Monkey
Stifel maintains Buy on Summit Therapeutics, $40 target By Investing.com - Investing.com Canada
Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? - Insider Monkey
New York State Common Retirement Fund Grows Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Principal Financial Group Inc. Acquires 147,003 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by StockNews.com - Defense World
(SMMT) Investment Analysis and Advice - Stock Traders Daily
Rhumbline Advisers Has $2.23 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group - MarketBeat
Equities Analysts Offer Predictions for SMMT Q1 Earnings - MarketBeat
Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN
StockNews.com Downgrades Summit Therapeutics (NASDAQ:SMMT) to Sell - MarketBeat
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Summit Therapeutics Stock Surges Amid Promising Trials - TipRanks
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
Summit Therapeutics Inc (SMMT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Chief Executive Officer |
Mar 26 '24 |
Buy |
3.75 |
30,000 |
112,500 |
30,000 |
| Zanganeh Mahkam | Chief Executive Officer |
Mar 27 '24 |
Buy |
3.72 |
26,000 |
96,720 |
520,814 |
| Dhingra Ankur | Chief Financial Officer |
Mar 26 '24 |
Buy |
3.75 |
100,000 |
375,000 |
354,958 |
0.03%
0.50%
大文字化:
|
ボリューム (24 時間):